Current evidence on the role of lipid lowering drugs in the treatment of psoriasis

被引:15
|
作者
Wang, Jiao [1 ,2 ]
Zhang, Shuo [1 ,2 ]
Xing, Meng [3 ]
Hong, Seokgyeong [1 ,2 ]
Liu, Liu [1 ,2 ]
Ding, Xiao-Jie [1 ,2 ]
Sun, Xiao-ying [1 ,2 ]
Luo, Ying [1 ,2 ]
Wang, Chun-xiao [1 ,2 ]
Zhang, Miao [1 ,2 ]
Li, Bin [2 ,4 ]
Li, Xin [1 ,2 ]
机构
[1] Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrated Tradit Chinese & Western M, Dept Dermatol, Shanghai, Peoples R China
[2] Shanghai Acad Tradit Chinese Med, Inst Dermatol, Shanghai, Peoples R China
[3] Shaanxi Hosp Tradit Chinese Med, Dept Dermatol, Xian, Peoples R China
[4] Tongji Univ, Shanghai Skin Dis Hosp, Sch Med, Shanghai, Peoples R China
基金
中国国家自然科学基金;
关键词
lipid metabolism; lipid-lowering drugs; statins; systematic review; meta-analysis; psoriasis; PCSK9; INHIBITION; CARDIOVASCULAR EVENTS; RHEUMATOID-ARTHRITIS; MONOCLONAL-ANTIBODY; DISEASE-ACTIVITY; STATINS; RISK; ATORVASTATIN; INFLAMMATION; RATIONALE;
D O I
10.3389/fmed.2022.900916
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Abnormal lipid distribution is observed in patients with psoriasis, which increases their risk for atherosclerosis. Lipid-lowering drugs have a certain curative effect in the treatment of psoriasis, but there is no relevant evidence-based medical evaluation. Objective: The purpose of this systematic evaluation was to assess the efficacy, safety, and potential mechanisms of action of lipid-lowering drugs for the treatment of psoriasis. Methods: The PubMed, Embase, Cochrane Central Register of Controlled Trials, Clinical Trial, Chinese National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database, and Wanfang Database were searched for relevant articles from inception to 31 December 2021. The RevMan 5.3 and Cochrane risk-of-bias tool were used for data analysis and risk assessment, respectively. The psoriasis area and severity index (PASI) score is the primary outcome indicator in clinical studies. Based on preclinical studies, we elucidated and mapped the action mechanisms of lipid-lowering drugs in the treatment of psoriasis. Results: The study included eight randomized controlled studies, four single-arm studies, and four in vitro studies. The results showed that lipid-lowering drugs, particularly statins, administered both orally and topically, can significantly improve psoriatic skin lesions and reduce the PASI scores [standardized mean difference, (SMD): -0.94; 95% CI: [-1.58, -0.31]; p = 0.004]. Oral statins performed best at week eight (SMD: -0.92; 95% CI: [-1.39, -0.44]; p = 0.0001). The mechanism of lipid-lowering drugs in the treatment of psoriasis may be related to the inhibition of keratinocyte proliferation, inhibition of CCL20-CCR6 interaction, and reduction in the levels of inflammatory factors. Limitations: There are few studies on lipid-lowering drugs and psoriasis, and their small sample sizes may render the evidence unconvincing. Conclusion: The present findings suggest that lipid-lowering drugs are relieving symptoms in psoriasis. Lipid-lowering drugs, particularly statins, can be used to treat psoriasis with good efficacy and few side effects.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] LIPID-LOWERING DRUGS
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 1985, 27 (695): : 74 - 76
  • [22] Lipid-lowering drugs and control of hypercholesterolemia in Poland: recent evidence
    Jankowski, Piotr
    Kloch-Badelek, Malgorzata
    Debicka-Dabrowska, Dorota
    POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ-POLISH ARCHIVES OF INTERNAL MEDICINE, 2011, 121 (05): : 164 - 170
  • [23] Serotonergic drugs - A possible role in the treatment of psoriasis?
    Thorslund, Kristofer
    Nordlind, Klas
    DRUG NEWS & PERSPECTIVES, 2007, 20 (08) : 521 - 525
  • [24] Lipid lowering drugs in diabetes - Lipid lowering has opthalamic benefits
    Sheth, HG
    Aslam, S
    Davies, N
    BRITISH MEDICAL JOURNAL, 2006, 332 (7552): : 1272 - 1273
  • [25] Effect of different types of hypoglycaemic drugs on psoriasis: current evidence
    Sun, X.
    Liu, L.
    Li, H.
    Zhou, Y.
    Luo, Y.
    Su, Y.
    Li, B.
    Li, X.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (01) : E22 - E22
  • [26] Dyslipidemia and progression of kidney disease: role of lipid-lowering drugs
    Vito M. Campese
    Clinical and Experimental Nephrology, 2014, 18 : 291 - 295
  • [27] Dyslipidemia and progression of kidney disease: role of lipid-lowering drugs
    Campese, Vito M.
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2014, 18 (02) : 291 - 295
  • [28] Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey
    Primatesta, P
    Poulter, NR
    BMJ-BRITISH MEDICAL JOURNAL, 2000, 321 (7272): : 1322 - 1325
  • [29] Lipid-lowering drugs and homocysteine - A comparison between statins and other lipid-lowering drugs
    Jankowski, P
    Kawecka-Jaszcz, K
    ATHEROSCLEROSIS, 2004, 172 (01) : 191 - 194
  • [30] COMBINED TREATMENT BY LIPID-LOWERING DRUGS IN ACUTE LIPEMIA IN MICE
    Korolenko, T. A.
    Gevorgyan, M. M.
    Voronina, N. P.
    Russkikh, G. S.
    Korolenko, T. P.
    Machova, E.
    CARDIOLOGY, 2018, 140 : 112 - 112